Healthcare Equipment and Supplies
Company Overview of Magellan Diagnostics, Inc.
Magellan Diagnostics, Inc., a medical device company, develops and manufactures point-of-care systems, clinical laboratory instruments, and analytical laboratory services focused on lead testing. Its products include LeadCare II, a blood lead testing system; LeadCare Ultra, which provides blood lead results for laboratories; and LeadCare Plus, a solution for laboratories with smaller volumes for performing lead testing in house. The company also provides various analytical services, such as lead and heavy metal exposure, monitoring exposure in employees, and testing. It offers solutions for clinicians, public health providers, managed care organizations, and families and communities. Magella...
101 Billerica Avenue
North Billerica, MA 01862
Founded in 2004
Key Executives for Magellan Diagnostics, Inc.
Chief Executive Officer and President
President of Trek Diagnostic Systems
Compensation as of Fiscal Year 2017.
Magellan Diagnostics, Inc. Key Developments
Magellan Diagnostics and PDXWildlife Partner to Identify Lead Exposure in Giant Pandas
Mar 16 17
Magellan Diagnostics announced an agreement to provide its LeadCare® II testing system to PDXWildlife at the Bifengxia Panda Base in Sichuan, China, for the study of lead exposure in captive giant pandas. Magellan Diagnostics' LeadCare II blood lead testing system is the only FDA cleared, rapid and portable system capable of providing a quantitative blood lead result in just three minutes. Although LeadCare II is primarily used in thousands of primary care settings in the United States to help doctors diagnose lead exposure in children and pregnant women quickly and easily, it is also used for identifying elevated blood lead levels in wildlife. The LeadCare II system is portable, allowing blood samples to be tested conveniently onsite through the spring breeding season. PDXWildlife expects to compile the results this summer and subsequently publish the results.
Magellan Diagnostics Inc. Signs Exclusive Distribution Agreement with Biofirm Technologies
Mar 7 17
Meridian Bioscience, Inc. announced that Magellan Diagnostics Inc. has signed an exclusive distribution agreement with Biofirm Technologies. Magellan Diagnostics LeadCare® II blood lead testing system is the only FDA cleared, rapid and portable system capable of providing a quantitative blood lead result in just three minutes. LeadCare II is used in thousands of pediatric and primary care settings in the United States to help doctors diagnose lead exposure quickly and easily, from just two drops of blood. Lead exposure is a global health threat because, even at low levels, it can cause behavioral and learning disabilities, hyperactivity and lower IQ, as well as hypertension and kidney dysfunction. A 2015 report by the World Health Organization on lead poisoning explains that African countries have a range of ongoing, lead-related public health concerns driven by numerous sources of lead to which African children may be exposed, often simultaneously. These sources include: lead paint in homes, on toys and on playground equipment; occupational sources from mining, smelting, battery manufacture/recycling, and e-waste processing; as well traditional medicines, cosmetics, and artisanal cookware. The report goes on to describe a health economic study that ‘conservatively estimated that, annually, around 98.2 million IQ points are lost in Africa due to lead exposure, translating into economic losses of $134.7 billion’. Distribution activities with Biofirm Technologies will begin immediately, focusing on developing awareness, at clinical and governmental levels, about the problem of lead poisoning. Education will address sources of lead exposure, consequences including deficits in fertility, fetal growth, intellectual development, learning and behavior as well as how portable testing can rapidly identify at-risk populations.
Magellan Diagnostics Signs Exclusive Partnership with Medcaptain Medical Technology to Expand Blood Lead Testing in China
Dec 20 16
Meridian Bioscience, Inc. announced that its Magellan Diagnostics business unit has signed an exclusive distribution agreement with MedCaptain Medical Technology Co., Ltd. Magellan Diagnostics’ LeadCare II blood lead testing system is the only FDA and CFDA cleared, rapid and portable system capable of providing a quantitative blood lead result in just three minutes. LeadCare II is used in thousands of pediatric and primary care settings in the United States to help doctors diagnose lead exposure quickly and easily. Distribution activities with MedCaptain will begin in January 2017. Partnering with Meridian Bioscience and Magellan Diagnostics, MedCaptain will invest in educating Chinese physicians and consumers about the risks and management of lead poisoning through a series of seminars and academic conferences.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|